A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

BACKGROUND: Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax. METHODS: This single-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Short, Nicholas J., Muftuoglu, Muharrem, Ong, Faustine, Nasr, Lewis, Macaron, Walid, Montalban-Bravo, Guillermo, Alvarado, Yesid, Basyal, Mahesh, Daver, Naval, Dinardo, Courtney D., Borthakur, Gautam, Jain, Nitin, Ohanian, Maro, Jabbour, Elias, Issa, Ghayas C., Qiao, Wei, Huang, Xuelin, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Bose, Prithviraj, Ravandi, Farhad, Delumpa, Ricardo, Abramova, Regina, Garcia-Manero, Guillermo, Andreeff, Michael, Cortes, Jorge, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329789/
https://www.ncbi.nlm.nih.gov/pubmed/37422688
http://dx.doi.org/10.1186/s13045-023-01476-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329789/
https://www.ncbi.nlm.nih.gov/pubmed/37422688
http://dx.doi.org/10.1186/s13045-023-01476-8

Ejemplares similares